Building a Renewed ImaGe After Head & Neck Cancer Treatment (BRIGHT) Multi-Site RCT

Medical University of South Carolina (MUSC) logo

Medical University of South Carolina (MUSC)




Mental Health Issue
Body Image
Body Image Disturbance
Psychosocial Impairment
Head and Neck Cancer


Behavioral: Attention Control
Behavioral: BRIGHT

Study type


Funder types



R37CA269385 (U.S. NIH Grant/Contract)
PRO 00110248

Details and patient eligibility


In this multi-center randomized clinical trial, head and neck cancer (HNC) survivors with clinically significant body image distress (BID) (N=180) will be randomized to BRIGHT (a brief video tele-cognitive behavioral therapy intervention) or Attention Control (AC, a manualized tele-supportive care intervention that controls for professional attention, dose, delivery method, and common factors). HNC survivors will complete IMAGE-HN (a validated patient-reported outcome measure [PROM] of HNC-related body image distress [BID]; primary endpoint), measures of psychological and social well-being and quality of life (QOL), and measures of theory-derived mechanisms of change underlying BRIGHT (mediators).

Full description

We will perform a multi-site randomized clinical trial (RCT) comparing BRIGHT with AC to test our hypotheses that BRIGHT reduces BID and improves psychological and social well-being and QOL at 2, 3, 6, and 9-months post-randomization by enhancing body image coping skills and decreasing unhelpful automatic thoughts. HNC survivors with clinically significant BID (N=180) from the Medical University of South Carolina (MUSC), Washington University School of Medicine (WUSM), and Henry Ford Health (HFH) will be randomized 1:1 to BRIGHT or AC. We will conduct semi-structured interviews with key stakeholders (n=10/site) and in-depth site visits to assess barriers and facilitators of the adoption of BRIGHT and develop an implementation toolkit to enhance the future adoption of BRIGHT into routine clinical care.


180 estimated patients




18+ years old


No Healthy Volunteers

Inclusion criteria

  1. Age > 18 years on the day of informed consent

  2. History of pathologically confirmed squamous cell carcinoma (or histologic variant) of the oral cavity, pharynx, larynx, nose/paranasal sinuses, carcinoma of a major or minor salivary gland, or cutaneous malignancy of the face or neck

  3. History of curative intent surgery with or without adjuvant therapy, with or without reconstruction

  4. Completion of oncologic treatment within 12 months of study enrollment (but no sooner than 6 weeks post-treatment completion)

  5. Cancer-free at the time of accrual

    -patients with known indolent malignancies (e.g., non-melanoma skin cancer, low risk thyroid cancer, untreated prostate cancer, etc) would not exclude a patient from the study

  6. No planned significant HNC ablative or reconstructive surgery (defined by a postoperative inpatient stay of at least three days) during the study intervention or follow-up period as determined by the HNC oncologic surgeon at the time of study accrual

  7. Willingness to be randomized to either BRIGHT or AC

  8. IMAGE-HN score > 22

Exclusion criteria

  1. Inability to speak or write English
  2. Pre-existing, ongoing CBT services for other disorders and the participant is not willing to discontinue the prior therapy for the duration of the proposed trial
  3. Initiation or adjustment (< 3 months of baseline) of psychotropic medication
  4. Severe psychiatric comorbidity (e.g., suicidal ideation, psychosis)

Trial design

Primary purpose

Supportive Care



Interventional model

Parallel Assignment


Double Blind

180 participants in 2 patient groups

Experimental group
BRIGHT is a manualized theory-based video tele-cognitive behavioral therapy (CBT) intervention delivered one-on-one by a licensed clinical psychologist.
Behavioral: BRIGHT
Attention Control
Active Comparator group
The attention control arm is a manualized video tele-supportive care intervention that addresses non-body image aspects of HNC survivorship.
Behavioral: Attention Control

Trial documents

Trial contacts and locations



Central trial contact

Evan M Graboyes, MD; Taylor McLeod, MPH

Data sourced from

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems